Skip to main content
. Author manuscript; available in PMC: 2023 Mar 1.
Published in final edited form as: J Orthop Res. 2021 May 12;40(3):553–564. doi: 10.1002/jor.25063

Figure 4.

Figure 4

Clinical assessment via lameness and flexion tests. (A) An average of ten lameness scores for limbs treated with various doses of sprifermin, HA, or placebo. (B) Combined scores from three sprifermin dose-treatment groups showed a significant reduction in lameness when compared to the placebo. (C) An average of ten flexion test scores for limbs received various intraarticular treatments. (D) Combined scores from three dose-treatment groups showed near to significant reduction compared to the placebo. Dotted line indicates median of the placebo group. n= 6 or 18, *p<0.05 by Kruskal-Wallis and Dunn’s multiple comparison test. In boxed plots, transverse lines show median and error bars represent SEM.